Monday, March 16, 2026
NIH-supported research reveals this remedy resulted in greater charges of illicit opioid abstinence than present commonplace of care.
In a medical trial supported by the Nationwide Institutes of Well being (NIH), a analysis workforce discovered that administering weekly injectable extended-release buprenorphine for remedy of opioid use dysfunction (OUD) throughout being pregnant led to greater charges of abstinence from illicit opioids than buprenorphine given day by day underneath the tongue (sublingual), one in all the usual strategies of remedy. Moreover, critical antagonistic occasions had been much less widespread in these receiving extended-release remedy. The findings, which assist the usage of this formulation of buprenorphine for treating OUD throughout being pregnant, had been printed in JAMA Inner Drugs.
“These findings are clinically useful for they present us that this injectable extended-release buprenorphine formulation is secure to make use of in being pregnant and ends in higher opioid abstinence outcomes in comparison with sublingual buprenorphine,” stated Nora D. Volkow, M.D., director of NIH’s Nationwide Institute on Drug Abuse (NIDA). “That is particularly related within the context of the continuing opioid overdose disaster and public well being emergency.”
Illicit opioid use and untreated OUD can have dire penalties throughout being pregnant, together with danger of deadly overdose for the mom and the event of neonatal opioid withdrawal syndrome (NOWS) and different antagonistic penalties for the newborn. Treating OUD in being pregnant with sublingual buprenorphine is efficient, but it surely has disadvantages, together with danger of misuse, doubtlessly poor adherence, and day by day fluctuating blood ranges generally known as peak-trough results that might inadequately mitigate opioid-related cravings and withdrawal, resulting in continued opioid use. The researchers on this research needed to see if utilizing a weekly formulation of subcutaneous (under-the-skin), extended-release buprenorphine injections throughout being pregnant—with the possibility of a month-to-month formulation for postpartum individuals who had been not breastfeeding—would possibly promote as good or higher opioid abstinence charges and NOWS outcomes.
In the multicenter trial, 140 pregnant adults had been randomized to obtain both injectable extended-release or sublingual buprenorphine (with or with out naloxone). The trial, supported by the NIDA Scientific Trials Community as a part of the NIH Serving to to Finish Habit Lengthy-term ® Initiative (NIH HEAL Initiative®), was the primary randomized trial testing extended-release buprenorphine for OUD in being pregnant and postpartum.
The researchers discovered that charges of illicit opioid abstinence throughout being pregnant, as measured by urine drug screens, had been considerably greater for these receiving weekly extended-release buprenorphine and had been non-inferior postpartum in comparison with individuals receiving sublingual buprenorphine. Whereas the proportion of individuals experiencing non-serious maternal antagonistic occasions didn’t differ between the kinds of remedies, they had been extra generally rated as medication-related within the extended-release group throughout being pregnant. Critical maternal antagonistic occasions had been much less widespread within the extended-release group all through the trial. NOWS outcomes didn’t differ between the remedy teams.
“We knew that injectable extended-release buprenorphine leads to superior charges of illicit opioid abstinence in non-pregnant adults, however there had been no accomplished randomized medical trial testing its use throughout being pregnant,” stated principal investigator and lead creator John Winhusen, Ph.D., professor of Psychiatry and Behavioral Neuroscience on the College of Cincinnati Faculty of Drugs. “It’s thrilling to share the outcomes of this trial, which have fast medical utility: this longer-acting remedy can safely and extra successfully assist remedy and restoration in pregnant sufferers.”
Should you or somebody you realize is struggling or in disaster, assist is out there. Name or textual content 988 or chat at 988lifeline.org. To discover ways to get assist for psychological well being, drug or alcohol situations, go to FindSupport.gov. If you’re able to find a remedy facility or supplier, you may go on to FindTreatment.gov or name 800-662-HELP (4357).
Concerning the Nationwide Institute on Drug Abuse (NIDA): NIDA is a element of the Nationwide Institutes of Well being, U.S. Division of Well being and Human Companies. NIDA helps many of the world’s analysis on the well being points of drug use and habit. The Institute carries out a big number of packages to tell coverage, enhance observe, and advance habit science. For extra details about NIDA and its packages, go to www.nida.nih.gov.
Concerning the Nationwide Institutes of Well being (NIH): NIH, the nation’s medical analysis company, contains 27 Institutes and Facilities and is a element of the U.S. Division of Well being and Human Companies. NIH is the first federal company conducting and supporting primary, medical, and translational medical analysis, and is investigating the causes, remedies, and cures for each widespread and uncommon illnesses. For extra details about NIH and its packages, go to www.nih.gov.
NIH…Turning Discovery Into Well being®
Reference
TJ Winhusen, et al. Prolonged-release versus Sublingual Buprenorphine in Being pregnant via 12-months Postpartum. JAMA Inner Drugs. DOI: 10.1001/jamainternmed.2026.0057
